A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company with a market capitalization of approximately $12.4 million, announced today that it has received U.S.

ERLANGEN, GERMANY AND VILNIUS, LITHUANIA - Mallia Therapeutics, a German biopharmaceutical company, and Northway Biotech, a ...

The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

Neehar Sachdeva, a content creator, redefined beauty standards by confidently embracing her natural bald look on her wedding ...

In modern medicine, alopecia treatment is essential since It reduces hair loss and encourages growth. Minoxidil, finasteride, corticosteroids, 5-alpha reductase inhibitors, and cyclosporine can ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...